EVONETIX

Company Overview

Evonetix, founded in 2015 as a spinout from the University of Cambridge, is developing and commercializing technologies for low-cost, high-fidelity DNA synthesis.

This technology is differentiated from other next-generation synthesis technologies by permitting longer, highly accurate DNA strands for a low cost. The main components of the synthesis technology include the use of silicon arrays; compatibility with both conventional chemicals as well as enzymatic DNA synthesis; and high-fidelity assembly process.

Producing high-quality DNA is important for synthetic biology applications including DNA data storage. In drug development, accurate DNA synthesis helps to understand the precise mechanism of a disease and how a drug interacts with it, by permitting test cells to be precisely modified. Accurate DNA synthesis permits precise cell-based screening assays to be designed for testing responses to drugs.

In October 2022, the company was shortlisted for the MSD Innovation Award at the Scrip Awards 2022 for its novel gene synthesis semiconductor technology that can further drive the rapidly growing field of synthetic biology.

Company's Business Segments

• Products : mRNA Vaccines, Antibody Engineering, Others
• Services : Benchtop Gene Synthesis Platform, Others